Phytogenic polyphenols as glycogen phosphorylase inhibitors: The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes

George A. Stravodimos; Ben A. Chetter; Efthimios Kyriakis; Anastassia L. Kantsadi; Demetra S.M. Chatzileontiadou; Vassiliki T. Skamnaki; Atsushi Kato; Joseph M. Hayes; Demetres D. Leonidas

doi:10.2174/0929867324666161118122534

Phytogenic polyphenols as glycogen phosphorylase inhibitors: The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes

George A. Stravodimos, Ben A. Chetter, Efthimios Kyriakis, Anastassia L. Kantsadi, Demetra S.M. Chatzileontiadou, Vassiliki T. Skamnaki, Atsushi Kato^*, Joseph M. Hayes, Demetres D. Leonidas

^*Corresponding author for this work

Hospital Pharmacy

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

Glycogen phosphorylase (GP) is a validated pharmaceutical target for the development of antihyperglycaemic agents. Phytogenic polyphenols, mainly flavonoids and pentacyclic triterpenes, have been found to be potent inhibitors of GP. These compounds have both pharmaceutical and nutraceutical potential for glycemic control in diabetes type 2. This review focuses mainly on the most successful (potent) of these compounds discovered to date. The protein-ligand interactions that form the structural basis of their potencies are discussed, highlighting the potential for exploitation of their scaffolds in the future design of new GP inhibitors.

Original language	English
Pages (from-to)	384-403
Number of pages	20
Journal	Current Medicinal Chemistry
Volume	24
Issue number	4
DOIs	https://doi.org/10.2174/0929867324666161118122534
State	Published - 2017/02/01

Keywords

Alpha-glucosidases
Antioxidants
Diabetes
Flavonoids
Glycogen phosphorylase
Pentacyclic triterpenes

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Drug Discovery
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/0929867324666161118122534

Cite this

Stravodimos, G. A., Chetter, B. A., Kyriakis, E., Kantsadi, A. L., Chatzileontiadou, D. S. M., Skamnaki, V. T., Kato, A., Hayes, J. M., & Leonidas, D. D. (2017). Phytogenic polyphenols as glycogen phosphorylase inhibitors: The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes. Current Medicinal Chemistry, 24(4), 384-403. https://doi.org/10.2174/0929867324666161118122534

@article{2f876b66e06e4b109c0b0be4e663b3fb,

title = "Phytogenic polyphenols as glycogen phosphorylase inhibitors: The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes",

abstract = "Glycogen phosphorylase (GP) is a validated pharmaceutical target for the development of antihyperglycaemic agents. Phytogenic polyphenols, mainly flavonoids and pentacyclic triterpenes, have been found to be potent inhibitors of GP. These compounds have both pharmaceutical and nutraceutical potential for glycemic control in diabetes type 2. This review focuses mainly on the most successful (potent) of these compounds discovered to date. The protein-ligand interactions that form the structural basis of their potencies are discussed, highlighting the potential for exploitation of their scaffolds in the future design of new GP inhibitors.",

keywords = "Alpha-glucosidases, Antioxidants, Diabetes, Flavonoids, Glycogen phosphorylase, Pentacyclic triterpenes",

author = "Stravodimos, {George A.} and Chetter, {Ben A.} and Efthimios Kyriakis and Kantsadi, {Anastassia L.} and Chatzileontiadou, {Demetra S.M.} and Skamnaki, {Vassiliki T.} and Atsushi Kato and Hayes, {Joseph M.} and Leonidas, {Demetres D.}",

note = "Publisher Copyright: {\textcopyright} 2017 Bentham Science Publishers.",

year = "2017",

month = feb,

day = "1",

doi = "10.2174/0929867324666161118122534",

language = "英語",

volume = "24",

pages = "384--403",

journal = "Current Medicinal Chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers",

number = "4",

}

Stravodimos, GA, Chetter, BA, Kyriakis, E, Kantsadi, AL, Chatzileontiadou, DSM, Skamnaki, VT, Kato, A, Hayes, JM & Leonidas, DD 2017, 'Phytogenic polyphenols as glycogen phosphorylase inhibitors: The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes', Current Medicinal Chemistry, vol. 24, no. 4, pp. 384-403. https://doi.org/10.2174/0929867324666161118122534

TY - JOUR

T1 - Phytogenic polyphenols as glycogen phosphorylase inhibitors

T2 - The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes

AU - Stravodimos, George A.

AU - Chetter, Ben A.

AU - Kyriakis, Efthimios

AU - Kantsadi, Anastassia L.

AU - Chatzileontiadou, Demetra S.M.

AU - Skamnaki, Vassiliki T.

AU - Kato, Atsushi

AU - Hayes, Joseph M.

AU - Leonidas, Demetres D.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Glycogen phosphorylase (GP) is a validated pharmaceutical target for the development of antihyperglycaemic agents. Phytogenic polyphenols, mainly flavonoids and pentacyclic triterpenes, have been found to be potent inhibitors of GP. These compounds have both pharmaceutical and nutraceutical potential for glycemic control in diabetes type 2. This review focuses mainly on the most successful (potent) of these compounds discovered to date. The protein-ligand interactions that form the structural basis of their potencies are discussed, highlighting the potential for exploitation of their scaffolds in the future design of new GP inhibitors.

AB - Glycogen phosphorylase (GP) is a validated pharmaceutical target for the development of antihyperglycaemic agents. Phytogenic polyphenols, mainly flavonoids and pentacyclic triterpenes, have been found to be potent inhibitors of GP. These compounds have both pharmaceutical and nutraceutical potential for glycemic control in diabetes type 2. This review focuses mainly on the most successful (potent) of these compounds discovered to date. The protein-ligand interactions that form the structural basis of their potencies are discussed, highlighting the potential for exploitation of their scaffolds in the future design of new GP inhibitors.

KW - Alpha-glucosidases

KW - Antioxidants

KW - Diabetes

KW - Flavonoids

KW - Glycogen phosphorylase

KW - Pentacyclic triterpenes

UR - http://www.scopus.com/inward/record.url?scp=85016162210&partnerID=8YFLogxK

U2 - 10.2174/0929867324666161118122534

DO - 10.2174/0929867324666161118122534

M3 - 総説

C2 - 27855623

AN - SCOPUS:85016162210

SN - 0929-8673

VL - 24

SP - 384

EP - 403

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

IS - 4

ER -

Phytogenic polyphenols as glycogen phosphorylase inhibitors: The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this